CA9 and neoplasm: Among the large series of small-molecule inhibitors, SLC-0111 showed not only high affinity for CA-IX in vitro, but also promising anti-tumor properties in cancer models; moreover, clinical trials of SLC-0111 in subjects with advanced solid tumors have suggested its utility in cancer therapy [37–39].